Vedolizumab for Crohn's disease

Crohn's disease (CD) is a chronic inflammatory disorder of unknown aetiology. Currently, approved therapies that include prednisone, anti-metabolites and TNF antagonists, are often ineffective and frequently cause adverse effects. As a result, patients with CD can develop serious complications...

Full description

Saved in:

Bibliographic Details
Published in:	Expert opinion on biological therapy Vol. 13; no. 3; p. 455
Main Authors:	Mosli, Mahmoud H, Feagan, Brian G
Format:	Journal Article
Language:	English
Published:	England 01-03-2013
Subjects:	Antibodies, Monoclonal, Humanized - therapeutic use Crohn Disease - drug therapy Gastrointestinal Agents - therapeutic use Humans Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Crohn's disease (CD) is a chronic inflammatory disorder of unknown aetiology. Currently, approved therapies that include prednisone, anti-metabolites and TNF antagonists, are often ineffective and frequently cause adverse effects. As a result, patients with CD can develop serious complications that adversely affect quality of life. Consequently, new treatment options are needed. This review discusses the potential role of vedolizumab, a humanised monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of CD. All randomised placebo-controlled trials that evaluated vedolizumab for the treatment of CD were reviewed and safety and efficacy data evaluated. Vedolizumab is an effective and well-tolerated drug that is an important advance for the treatment of CD.
ISSN:	1744-7682
DOI:	10.1517/14712598.2013.770835